Mechanism of fibrosis in experimental tacrolimus nephrotoxicity

Transplantation

Volumn 64, Issue 12, 1997, Pages 1829-1837

  Shihab, Fuad S ^a,b   Bennett, William M ^c   Tanner, Amie M ^a   Andoh, Takeshi F ^c  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIGLYCAN; COLLAGEN TYPE 1; FIBRONECTIN; IMMUNOSUPPRESSIVE AGENT; MATRIX PROTEIN; TACROLIMUS; TENASCIN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL MODEL; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE COURSE; ENZYMURIA; HYPERRENINEMIA; KIDNEY CONCENTRATING CAPACITY; KIDNEY FIBROSIS; KIDNEY TUBULE NECROSIS; MALE; NEPHROTOXICITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN DISORDER; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; EXTRACELLULAR MATRIX; EXTRACELLULAR MATRIX PROTEINS; FIBROSIS; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GENE EXPRESSION; KIDNEY CORTEX; KIDNEY DISEASES; KIDNEY MEDULLA; MALE; PLASMINOGEN ACTIVATOR INHIBITOR 1; RATS; RATS, SPRAGUE-DAWLEY; RENIN; SODIUM CHLORIDE, DIETARY; TACROLIMUS; TENASCIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 0031463832     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199712270-00034     Document Type: Conference Paper

References (58)

1. Starzl TE, Todo S, Fung J, Demetris AJ, Venkataramman R, Jain A. FK506 for liver, kidney, and pancreas transplantation. Lancet 1989; 2: 1000.
2. Demetris AJ, Fung JJ, Todo S, et al. Conversion of liver allograft recipients from cyclosporine to FK506 immunosuppressive therapy: a clinicopathologic study of 96 patients. Transplantation 1992; 53: 1056.
3. Wagner K, Herget S, Heemann U. Experimental and clinical experience with the use of tacrolimus (FK506) in kidney transplantation. Clin Nephrol 1996; 45: 332.
4. Tanaka H, Kuroda A, Marusawa H, Hashimoto M, Hatanaka H, Kino T. Physicochemical properties of FK506, a novel immunosuppressant isolated from Streptomyces tsukubaensis. Transplant Proc 1987; 19: 11.
5. Sawada S, Suzuki G, Kawase Y, Takaku F. Novel immunosuppressive agent, FK506: in vitro effects on the cloned T cell activation. J Immunol 1987; 139: 1797.
6. Harding MW, Galat A, Uehling DE, Schreiber SL. A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase. Nature 1989; 341: 758.
7. Tocci MJ, Maktovich DA, Collier KA, et al. The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes. J Immunol 1989; 143: 718.
8. McCauley J, Van-Thiel DH, Starzl TE, Puschett JB. Acute and chronic renal failure in liver transplantation. Nephron 1990; 55: 121.
9. McCauley J. The nephrotoxicity of FK506 as compared with cyclosporine. Curr Opin Nephrol Hypertens 1993; 662.
10. Randhawa PS, Tsamandas AC, Magnone M, et al. Microvascular changes in renal allografts associated with FK506 (tacrolimus) therapy. Am J Surg Pathol 1996; 20: 306.
11. Bennett WM, Burdmann EA, Andoh TF, Houghton DC, Lindsley J, Elzinga LW. Nephrotoxicity of immunosuppressive drugs. Nephrol Dial Transplant 1994; 9: 141.
12. Andoh TF, Burdmann EA, Lindsley J, Houghton DC, Bennett WM. Enhancement of FK506 nephrotoxicity by sodium depletion in an experimental rat model. Transplantation 1994; 57: 483.
13. Stillman IE, Andoh TF, Burdmann EA, Bennett WM, Rosen S. FK506 nephrotoxicity: morphologic and physiologic characterization of a rat model. Lab Invest 1995; 73: 794.
14. Andoh TF, Burdmann EA, Lindsley J, Houghton DC, Bennett WM. Functional and structural characteristics of experimental FK506 nephrotoxicity. Clin Exp Pharmacol Physiol 1995; 22: 646.
15. Border WA, Noble NA. Transforming growth factor β in tissue fibrosis. N Engl J Med 1994; 331: 1286.
16. Nakamura T, Miller D, Ruoslahti E, Border WA. Production of extracellular matrix by glomerular epithelial cells is regulated by transforming growth factor-β1. Kidney Int 1990; 41: 1213.
17. Ignotz RA, Massague J. Transforming growth factor beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem 1986; 261: 4337.
18. Balza E, Borsi L, Allemanni G, Zardi L. Transforming growth factor β regulates the levels of different fibronectin isoforms in normal human cultured fibroblasts. FEBS Lett 1988; 228: 42.
19. Laiho M, Saksela O, Keski-Oja J. Transforming growth factor-β induction of type-1 plasminogen activator inhibitor. J Biol Chem 1987; 262: 17467.
20. Ruscetti FW, Palladino MA. Transforming growth factor-β and the immune system. Prog Growth Factor Res 1991; 3: 159.
21. Frizell E, Abraham A, Doolittle M, et al. FK506 enhances fibrogenesis in in vitro and in vivo models of liver fibrosis in rats. Gastroenterology 1994; 107: 492.
22. Han CW, Imamura M, Hashino S, et al. Differential effects of the immunosuppressants cyclosporin A, FK506 and KM2210 on cytokine gene expression. Bone Marrow Transplant 1995; 15: 733.
23. Shihab FS, Andoh TF, Tanner AM, et al. Role of transforming growth factor-β1 in experimental chronic cyclosporine nephropathy. Kidney Int 1996; 49: 1141.
24. Khanna A, Li B, Stenzel KH, Suthanthiran M. Regulation of new DNA synthesis in mammalian cells by cyclosporine: demonstration of a transforming growth factor β-dependent mechanism of inhibition of cell growth. Transplantation 1994; 57: 577.
25. Shehata M, Cope GH, Johnson TS, Raftery AT, El Nahas AM. Cyclosporine enhances the expression of TGF-β in the juxtaglomerular cells of the rat kidney. Kidney Int 1995; 48: 1487.
26. Burdmann FA, Andoh TF, Rosen S, et al. Experimental nephrotoxicity, hepatotoxicity and pharmacokinetics of cyclosporin G versus cyclosporin A. Kidney Int 1994; 45: 684.
27. Derynck R, Jarrett JA, Chen EY, Goeddel DV. The murine transforming growth factor-β precursor. J Biol Chem 1986; 261: 4377.
28. Zeheb R, Gelehrter TD. Cloning and sequencing of cDNA for the rat plasminogen activator inhibitor-1. Gene 1988; 73: 459.
29. Fisher LW, Termine JD, Young MF. Deduced protein sequence of small proteoglycan I (biglycan) shows homology with proteoglycan II (decorin) and several nonconnective tissue proteins in a variety of species. J Biol Chem 1989; 264: 4571.
30. Genovese C, Rowe D, Kream B. Construction of DNA sequences complementary to rat α1 and α2 collagen mRNA and their use in studying the regulation of type I collagen synthesis by 1,25-dihydroxyvitamin D. Biochemistry 1984; 23: 6210.
31. Fort P, Marty L, Piechaczyk M, et al. Various rat adult tissues express only one major mRNA species from the glyceraldehyde-3-phosphate dehydrogenase multigenic family. Nucleic Acids Res 1985; 13: 1431.
32. Shihab FS, Yamamoto T, Nast CC, et al. Transforming growth factor-β and matrix protein expression in acute and chronic rejection of human renal allografts. J Am Soc Nephrol 1995; 6: 286.
33. Shihab FS, Tanner AM, Shao Y, Weffer MI. Expression of TGF-β1 and matrix proteins is elevated in rats with chronic rejection. Kidney Int 1996; 50: 1904.
34. Llanos A, Cieza J, Bernardo J, et al. Effect of salt supplementation on amphotericin B nephrotoxicity. Kidney Int 1991; 40: 302.
35. Rosen S, Greenfeld Z, Brezis M. Chronic cyclosporine-induced nephropathy in the rat. Transplantation 1990; 49: 445.
36. Andoh TF, Burdmann EA, Franceschini N, Houghton DC, Bennett WM. Comparison of acute rapamycin nephrotoxicity with cyclosporine and FK506. Kidney Int 1996; 50: 1110.
37. Venkataramanan R, Swaminathan A, Prasad T, et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet 1995; 29: 404.
38. Jusko WJ, Piekoszewski W, Klintmalm GB, et al. Pharmacokinetics of tacrolimus in liver transplant patients. Clin Pharmacol Ther 1995; 57: 281.
39. Gruber SA, Hewitt JM, Sorenson AL, et al. Pharmacokinetics of FK506 after intravenous and oral administration in patients awaiting renal transplantation. J Clin Pharmacol 1994; 34: 859.
40. Fealy MJ, Umansky WS, Bickel KD, Nino JJ, Morris RE, Press BH. Efficacy of rapamycin and FK 506 in prolonging rat hind limb allograft survival. Ann Surg 1994; 219: 88.
41. Tanabe M, Todo S, Murase N, et al. Combined immunosuppressive therapy with low dose FK506 and antimetabolites in rat allogeneic heart transplantation. Transplantation 1994; 58: 23.
42. Hashimoto T, Zhong RZ, Garcia BM, et al. Treatment with FK506 prevents rejection of rat colon allografts. Transplantation 1994; 57: 1548.
43. +-ATPase activity by FK506 involves calcineurin. Kidney Int 1994; 46: 647.
44. Roberts AB, Joyce ME, Bolander ME, Sporn MB. Transforming growth factor-β: a multifunctional effector of both soft and hard tissue regeneration. In: Westermark B, Betsholtz C, Hokfelt B, eds. Growth factors in health and disease. Amsterdam: Elsevier, 1990: 89.
45. Obberghen-Schilling EV, Roche NS, Flanders KC, Sporn MB, Roberts AB. Transforming growth factor β1 positively regulates its own expression in normal and transformed cells. J Biol Chem 1988; 263: 7741.
46. Baricos WH, Cortez SL, El Dahr SS, Schnaper HW. ECM degradation by cultured human mesangial cells is mediated by a PA/plasmin/MMP-2 cascade. Kidney Int 1995; 47: 1039.
47. Shull MM, Ormsby I, Kier AB, et al. Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease. Nature 1992; 359: 693.
48. Goes N, Urmson J, Ramassar V, Halloran PF. Ischemic acute tubular necrosis induces an extensive local cytokine response. Transplantation 1995; 59: 565.
49. Yamada K, Sugisaki Y, Akimoto M, Yamanaka N. FK506-induced juxtaglomerular apparatus hyperplasia and tubular damage in rat kidney: morphologic and biologic analysis. Transplant Proc 1992; 24: 1396.
50. Burdmann EA, Andoh TF, Nast CC, et al. Prevention of experimental cyclosporin-induced interstitial fibrosis by losartan and enalapril. Am J Physiol 1995; 269: F491.
51. Shihab FS, Andoh TF, Tanner AM, Bennett WM. Angiotensin II blockade ameliorates fibrosis and decreases TGF-β1 expression in chronic cyclosporine nephropathy. J Am Soc Nephrol 1996; 7: 1846.
52. Ichikawa I, Harris RC. Angiotensin actions in the kidney: renewed insight into the old hormone. Kidney Int 1991; 40: 583.
53. Keane WF, Anderson S, Aurell M, de Zeeuw D, Narins G, Povar G. Angiotensin converting enzyme inhibitors and progressive renal insufficiency. Ann Intern Med 1993; 118: 577.
54. Kakinuma Y, Kawamura T, Bills T, Yoshioka T, Ichikawa I, Fogo A. Blood pressure-independent effect of angiotensin inhibition on vascular lesions of chronic renal failure. Kidney Int 1992; 42: 46.
55. Itoh H, Mukoyama M, Pratt RE, Gibbons GH, Dzau VJ. Multiple autocrine growth factors modulate vascular smooth muscle cell growth responses to angiotensin II. J Clin Invest 1993; 91: 2268.
56. Kagami S, Border WA, Miller DE, Noble NA. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-β expression in rat glomerular mesangial cells. J Clin Invest 1994; 93: 2431.
57. Wolf G, Sharma K, Chen Y, Ericksen M, Ziyadeh FN. High glucose-induced proliferation in mesangial cells is reversed by autocrine TGF-β. Kidney Int 1992; 42: 647.
58. Olson JA Jr, Shiverick KT, Ogilvie S, Buhi WC, Raizada MK. Angiotensin II induces secretion of plasminogen activator inhibitor 1 and a tissue metalloprotease inhibitor-related protein from rat brain astrocytes. Proc Natl Acad Sci USA 1991; 88: 1928.